Gene Solutions Malaysia continues to advance early cancer detection in Malaysia together with NCSM

About 50 participants at the Caritas Center
About 50 participants at the Caritas Center

Building on the success of our first Cancer Screening and Detection Workshop on 10th and 11th of August, we took the next step on our journey in Ipoh, Perak, on September 7th and 8th. Hosted at the NCSM-Caritas center, this event brought together a truly diverse group of about 50 participants—cancer survivors, patients, caregivers, and healthcare professionals. Each came with their own story, but we were all united by a shared hope that early detection can save lives.

Mr. Raja Iswara (above), Dr. Ahmad Rosli (below) during the presentation
Mr. Raja Iswara (above), Dr. Ahmad Rosli (below) during the presentation

Throughout the workshop, Dr. Ahmad Rosli and Mr. Raja Iswara encouraged us all to take action, stressing the importance of early detection in fighting cancer. Their words reminding us that advanced technologies hold the potential to bring real change. Meanwhile, Dr. Malwinder Singh, a Consultant Oncologist from Pantai Hospital Kuala Lumpur, added a deeper layer to this conversation, showing us how early detection isn’t just about catching cancer sooner, but it’s about offering a better chance in giving a hope for better outcomes.

Dr. Malwinder Singh (right) during their presentation
Dr. Malwinder Singh (right) during their presentation

This time in Ipoh is part of something larger. In collaboration with NCSM, we continue to engage communities across Malaysia in meaningful discussions, highlighting the potential of Multi-Cancer Early Detection and ctDNA technologies. Together, we’re building awareness and fostering a growing commitment in cancer care. We believe this collective effort is paving the way for a future where more lives are saved, one early detection at a time.

And our journey is far from over—our next stop will be in Melaka.

About Gene Solutions Malaysia

Gene Solutions established its operations and services in Malaysia in 2023 and is committed to provide the local community access to next-generation genetic tests that support reproductive health and clinical oncology. In the field of clinical oncology, personalized minimal residual disease (MRD) detection, and multi-cancer early detection (MCED) tests using advanced ctDNA technology are among some of the products available. Partnering with local laboratory partners Premier Integrated Lab and Innoquest Malaysia, Gene Solutions Malaysia is committed to enhancing healthcare with their innovative genetic solutions.

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More